Key Points:
- Starboard Value significantly reduces its stake in Pfizer by 50% amid concerns over recent acquisitions.
- Analyst price targets suggest a potential 27.67% upside from the current stock price.
- GuruFocus estimates indicate a possible 20.58% gain looking forward.
Starboard Value, a prominent hedge fund, has made a notable adjustment to its investment in Pfizer Inc. (PFE, Financial), slashing its holdings by nearly half during the first quarter. Previously holding a substantial $1 billion stake, Starboard now retains 7.7 million shares. This strategic move comes amidst the hedge fund's ongoing critique of Pfizer's valuation regarding recent acquisition activities.
Analyst Predictions for Pfizer
Wall Street analysts have provided insightful one-year price targets for Pfizer Inc (PFE, Financial), with projections offering a broad perspective on its potential value. The average target price stands at $28.85, featuring a range from a high of $41.43 to a low of $23.00. This suggests a significant potential upside of 27.67% from the current trading price of $22.60. Investors seeking further details can explore the Pfizer Inc (PFE) Forecast page.
The consensus recommendation from 25 brokerage firms lands at an average rating of 2.6, categorizing Pfizer's stock as a "Hold." The rating scale ranges from 1, reflecting a Strong Buy, to 5, indicating a Sell position.
Understanding Pfizer's GF Value Estimate
GuruFocus delivers a comprehensive assessment with its estimated GF Value for Pfizer Inc (PFE, Financial). The estimate suggests Pfizer's stock could achieve a value of $27.25 within the year, indicating a potential upside of 20.58% from its current price of $22.60. This estimation is based on historical trading multiples, past business growth, and forecasts of the company's future performance. For a deeper dive, please visit the Pfizer Inc (PFE) Summary page.
